Standaard Boekhandel gebruikt cookies en gelijkaardige technologieën om de website goed te laten werken en je een betere surfervaring te bezorgen.
Hieronder kan je kiezen welke cookies je wilt inschakelen:
Technische en functionele cookies
Deze cookies zijn essentieel om de website goed te laten functioneren, en laten je toe om bijvoorbeeld in te loggen. Je kan deze cookies niet uitschakelen.
Analytische cookies
Deze cookies verzamelen anonieme informatie over het gebruik van onze website. Op die manier kunnen we de website beter afstemmen op de behoeften van de gebruikers.
Marketingcookies
Deze cookies delen je gedrag op onze website met externe partijen, zodat je relevantere communicatie op onze eigen website en relevantere advertenties van Standaard Boekhandel op externe platformen te zien krijgt.
Je kan maximaal 250 producten tegelijk aan je winkelmandje toevoegen. Verwijdere enkele producten uit je winkelmandje, of splits je bestelling op in meerdere bestellingen.
They Do Well Who Do Good is a collection of articles written from 2000 to 2010 that document the changes in the Japan health care system and pharma industry. Changes considered impossible in the past became routine. As the decade ended, optimists and game changers leave the pessimists and status quo keepers behind. An attractive health care system evolved to care for an aging population with chronic diseases versus a young population with acute diseases. Japan wants the best health care the world has to offer, but choices must be made because resources to pay the bill are limited. In the beginning of the decade, you could compare Japanese pharma companies to a convoy of ships. Some big, some small, some fast, some slow, but all moved together. Ten years later, the convoy analogy was no longer useful. Some went abroad, others stayed home. Some divested noncore businesses; others did not. Some merged; others choose to go alone. Some changed their business models and cultures. Other rejected change and held on to their past. They Do Well Who Do Good is an insider's perspective on what it takes to succeed in Japan's pharma market.